Rigel Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, RIGL, Rigel Pharmaceuticals Inc, priceseries

Rigel Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
3.08
Close
3.09
High
3.17
Low
3.04
Previous Close
3.04
Daily Price Gain
0.05
YTD High
3.17
YTD High Date
Mar 7, 2022
YTD Low
2.19
YTD Low Date
Feb 24, 2022
YTD Price Change
0.35
YTD Gain
12.77%
52 Week High
4.62
52 Week High Date
Jun 29, 2021
52 Week Low
2.19
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-0.58
52 Week Gain
-15.80%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 29. 2017
2.54
Oct 23. 2017
3.75
16 Trading Days
47.78%
Link
LONG
Aug 24. 2018
2.81
Sep 11. 2018
3.21
11 Trading Days
14.12%
Link
LONG
Jun 26. 2019
2.36
Jul 12. 2019
2.52
11 Trading Days
6.95%
Link
LONG
Oct 21. 2019
1.68
Nov 18. 2019
2.25
20 Trading Days
34.05%
Link
LONG
Jan 13. 2020
2.17
Jan 24. 2020
2.56
8 Trading Days
18.04%
Link
LONG
Apr 6. 2020
1.59
Apr 15. 2020
1.67
6 Trading Days
5.27%
Link
LONG
Jul 13. 2020
2.16
Jul 22. 2020
2.84
7 Trading Days
31.52%
Link
LONG
Nov 20. 2020
2.75
Dec 29. 2020
3.51
25 Trading Days
27.81%
Link
LONG
Feb 1. 2021
3.78
Feb 23. 2021
4.41
15 Trading Days
16.62%
Link
LONG
Jun 2. 2021
3.77
Jun 30. 2021
4.34
20 Trading Days
15.17%
Link
Company Information
Stock Symbol
RIGL
Exchange
NasdaqGS
Company URL
http://www.rigel.com
Company Phone
-
CEO
Raul R. Rodriguez
Headquarters
California
Business Address
-
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001034842
About

Rigel Pharmaceuticals, Inc. is a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The company focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Its current product development programs include Fostamatinib Oral SYK Inhibitor and R348 Topical Ophthalmic JAK/SYK Inhibitor. Rigel Pharmaceuticals was founded by Donald G. Payan, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Description

Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The company's clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It is also developing two oncology product candidates, which are in Phase I and Phase II. Rigel Pharmaceuticals, Inc. has license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; Bristol-Myers Squibb Company for the discovery, development, and commercialization of cancer immunotherapies; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of an oncology program; and Daiichi Sankyo to pursue research related to ligases. The company was founded in 1996 and is based in South San Francisco, California.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading